NATHAN FOWLER to Antigens, CD19
This is a "connection" page, showing publications NATHAN FOWLER has written about Antigens, CD19.
Connection Strength
0.498
-
Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma. Leuk Lymphoma. 2024 Mar; 65(3):323-332.
Score: 0.181
-
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022 02; 28(2):325-332.
Score: 0.157
-
Prolonged cytopenia following CD19 CAR T?cell therapy is linked with bone marrow infiltration of clonally expanded IFN?-expressing CD8 T?cells. Cell Rep Med. 2023 08 15; 4(8):101158.
Score: 0.044
-
Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood. 2022 08 04; 140(5):504-515.
Score: 0.041
-
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2021 10 01; 106(10):2667-2672.
Score: 0.039
-
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 08 25; 4(16):3943-3951.
Score: 0.036